COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Community-Acquired Pneumonia (CAP) Surveillance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01416506
Recruitment Status : Completed
First Posted : August 15, 2011
Last Update Posted : November 5, 2013
Information provided by (Responsible Party):

Brief Summary:
Prospective, non-interventional, multi-center study. 7 investigative centers will involved in China. Around 560 CAP outpatients or inpatients will be screened until 56 M. pneumoniae isolates collected.

Condition or disease Intervention/treatment
Pneumonia Other: No Drug

Layout table for study information
Study Type : Observational
Actual Enrollment : 560 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Community-Acquired Pneumonia (CAP) Mycoplasma Surveillance
Study Start Date : September 2010
Actual Primary Completion Date : August 2012
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Group/Cohort Intervention/treatment
Group 1 Other: No Drug
It's a surveillance

Primary Outcome Measures :
  1. In vitro Minimal Inhibitory Concentration Detection [ Time Frame: Up to 27 months ]

Secondary Outcome Measures :
  1. In vitro Gene Mutation Detection [ Time Frame: Up to 15 months ]

Biospecimen Retention:   Samples With DNA
whole blood, serum

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Chinese adult (male or female) >/= 18 years old

Inclusion Criteria:

  • Chinese adult (male or female) ≥18 years old
  • Outpatients or inpatients who suffer from CAP

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01416506

Layout table for location information
Many Locations, China
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT01416506    
Other Study ID Numbers: 15465
NN1010CN ( Other Identifier: Company Internal )
First Posted: August 15, 2011    Key Record Dates
Last Update Posted: November 5, 2013
Last Verified: November 2013
Keywords provided by Bayer:
Pneumonia, surveillance
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections